ST. LOUIS, Mo.--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) announced today that it has entered into a multiyear agreement with Medtronic (NYSE: MDT) to advance availability in the U.S. of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.
Help employers find you! Check out all the jobs and post your resume.
